MX2022008770A - Muteinas de la il2. - Google Patents

Muteinas de la il2.

Info

Publication number
MX2022008770A
MX2022008770A MX2022008770A MX2022008770A MX2022008770A MX 2022008770 A MX2022008770 A MX 2022008770A MX 2022008770 A MX2022008770 A MX 2022008770A MX 2022008770 A MX2022008770 A MX 2022008770A MX 2022008770 A MX2022008770 A MX 2022008770A
Authority
MX
Mexico
Prior art keywords
muteins
treatment
human disease
present disclosures
disclosures
Prior art date
Application number
MX2022008770A
Other languages
English (en)
Inventor
Scott Alan Mccauley
Steve Kauder
Jan Emmerich
Original Assignee
Synthekine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthekine Inc filed Critical Synthekine Inc
Publication of MX2022008770A publication Critical patent/MX2022008770A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente divulgación se refiere a muteínas de la IL2 y sus usos en el tratamiento de enfermedades humanas.
MX2022008770A 2020-01-14 2021-01-14 Muteinas de la il2. MX2022008770A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062960847P 2020-01-14 2020-01-14
PCT/US2021/013514 WO2021146481A1 (en) 2020-01-14 2021-01-14 Il2 muteins

Publications (1)

Publication Number Publication Date
MX2022008770A true MX2022008770A (es) 2022-10-07

Family

ID=76863259

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022008770A MX2022008770A (es) 2020-01-14 2021-01-14 Muteinas de la il2.

Country Status (10)

Country Link
US (1) US20230210951A1 (es)
EP (1) EP4090354A4 (es)
JP (1) JP2023510871A (es)
KR (1) KR20220127866A (es)
CN (1) CN115066253A (es)
AU (1) AU2021207661A1 (es)
CA (1) CA3166009A1 (es)
IL (1) IL294070A (es)
MX (1) MX2022008770A (es)
WO (1) WO2021146481A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115362168A (zh) 2020-01-14 2022-11-18 辛德凯因股份有限公司 偏向化il2突变蛋白方法和组合物
WO2024086739A1 (en) 2022-10-20 2024-04-25 Synthekine, Inc. Methods and compositions of il12 muteins and il2 muteins

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9567399B1 (en) * 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
AU2017359172A1 (en) * 2016-11-08 2019-05-16 Delinia, Inc. IL-2 variants for the treatment of autoimmune diseases
JP7269249B2 (ja) * 2017-11-10 2023-05-08 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ Ｉｌ２ｒベータ／共通ガンマ鎖抗体
JP2021528105A (ja) * 2018-06-22 2021-10-21 キュージーン インコーポレイテッドＣｕｇｅｎｅ Ｉｎｃ． インターロイキン−２バリアントおよびその使用方法

Also Published As

Publication number Publication date
AU2021207661A1 (en) 2022-07-21
EP4090354A4 (en) 2024-05-22
CN115066253A (zh) 2022-09-16
KR20220127866A (ko) 2022-09-20
IL294070A (en) 2022-08-01
EP4090354A1 (en) 2022-11-23
CA3166009A1 (en) 2021-07-22
US20230210951A1 (en) 2023-07-06
JP2023510871A (ja) 2023-03-15
WO2021146481A1 (en) 2021-07-22

Similar Documents

Publication Publication Date Title
JOP20220179A1 (ar) N4-هيدروكسي سيتيدين ومشتقات واستخدامات مضادة للفيروسات مرتبطة بها
MX2022008770A (es) Muteinas de la il2.
MX2021010323A (es) Compuestos bicíclicos de heterociclilo y usos de este.
Gileva et al. Hirudotherapy
Lou et al. Analysis of the effectiveness of basic fibroblast growth factor treatment on traumatic perforation of the tympanic membrane at different time points
NO20071238L (no) Fremgangsmater for leging av skader ved human IL-18 administrering
EA200870108A1 (ru) Мутанты фсг
WO2022043273A3 (en) Oral care composition comprising a fructanase
PT1585513E (pt) Utilizacao de acido docosa-hexaenoico como substancia activa para o tratamento de lipodistrofia
EP4067504A4 (en) USE OF SYNAPTOTAGMINE-7 IN THE DIAGNOSIS AND TREATMENT OF BIPOLAR DISORDER
Woolf My honest note to hospital staff changed everything—combining healing for body and mind
HUP0301451A2 (hu) CGMP PDE5 inhibitorok alkalmazása perifériás érbetegségek, perifériás neuropátiák és autonóm neuropátiák kezelésére szolgáló gyógyszerkészítmények elżállítására
Castillo et al. Reply to:“Wound management strategies in Stevens-Johnson syndrome/toxic epidermal necrolysis: An unmet need”
Pasek et al. Wound treatment after congenital syndactyly separation with 100% oxygen therapy: A case report
WO2022240804A3 (en) Methods of treating sickle cell disorder and related conditions
Baxi et al. Immediate Effects of Kinesio Taping on Lung Functions, Chest Expansion and Dyspnoea in COPD Patients.
Nagarajan et al. Effectiveness of varmam therapy in patchavatham (hemiplegia)-a case report
Koren et al. Unusual primary and secondary facial blast injuries
ATE466587T1 (de) Valeriana officinalis extrakt zur behandlung von schlafapnoe oder hypopnoe
Thenmozhi et al. Hyperbaric oxygen therapy: Therapeutic role in various cases–A case series
Drouin et al. A double-blind, placebo-controlled, randomized trial of XP-828L (800 mg) on the quality of life and clinical symptoms of patients with mild-to-moderate psoriasis
MX2023000732A (es) Anticuerpos anti- alfa-4-beta-7.
TWD231873S (zh) 手持按摩器
RU2009119225A (ru) Способ лечения и профилактики кокцидиозов норок
Pasek et al. Possibilities of physical medicine in the treatment of wound of tarsal joint